
CLAIMS

1. A compound of formula **IA:**




IA

or a pharmaceutically acceptable salt thereof; wherein

Y is a C_1-C_6 aliphatic chain wherein one methylene unit of the aliphatic chain are optionally replaced with NR^0 or C(O) ;

Ring A is



;

J^3 is H or C_{1-4}alkyl wherein 1 methylene unit of the alkyl group can optionally be replaced with O, NH, N(C_{1-4}alkyl), or S and optionally substituted with 1-3 halo;

Q is phenyl or pyridyl substituted in the ortho position, the para position, or in both the ortho and the para position;

R^5 is a 3-7 membered monocyclic fully saturated, partially unsaturated, or aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-10 membered bicyclic fully saturated, partially unsaturated, or aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R^5 is optionally substituted with 1-5 J^5 groups;

L is a C_{1-4}alkyl chain wherein up to two methylene units of the alkyl chain are optionally replaced with O, NR^6, S, –C(O)–, –SO–, or $–SO_2–$;

R^0 is H or C_1-C_6alkyl wherein one methylene unit of the alkyl chain can be optionally replaced with O, NH, N(C_{1-4}alkyl), or S;

R^1 is H or C_1-C_6alkyl;

R^2 is H, C_1-C_6alkyl, –(C_2-C_6alkyl)–Z or a 4-8 membered cyclic ring containing 0-2 nitrogen atoms; wherein said ring is bonded via a carbon atom and is optionally substituted with one occurrence of J^Z;

or R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein said heterocyclic ring is optionally substituted with one occurrence of J^{Z1};

J^{Z1} is $-(X)_t-CN$, C_1-C_6alkyl, or $-(X)_r-Z$;

X is C_1-C_4alkyl;

each t, r and m is independently 0 or 1;

Z is $-NR^3R^4$;

R^3 is H or C_1-C_2alkyl;

R^4 is H or C_1-C_6alkyl;

or R^3 and R^4, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein said ring is optionally substituted with one occurrence of J^Z;

R^6 is H, or C_1-C_6alkyl;

J^Z is independently NH_2, $NH(C_{1-4}aliphatic)$, $N(C_{1-4}aliphatic)_2$, halogen, C_{1-4}aliphatic, OH, $O(C_{1-4}aliphatic)$, NO_2, CN, CO_2H, $CO(C_{1-4}aliphatic)$, $CO_2(C_{1-4}aliphatic)$, $O(haloC_{1-4}aliphatic)$, or $haloC_{1-4}aliphatic$;

J^5 is halo, oxo, CN, NO_2, X^1-R, or $-(X^1)_p-Q^4$;

X^1 is C_{1-10}aliphatic; wherein 1-3 methylene units of said C_{1-10}aliphatic are optionally replaced with –NR'–, -O-, -S-, C(=NR'), C(O), $S(O)_2$, or S(O); wherein X^1 is optionally and independently substituted with 1-4 occurrences of NH_2, $NH(C_{1-4}aliphatic)$, $N(C_{1-4}aliphatic)_2$, halogen, C_{1-4}aliphatic, OH, $O(C_{1-4}aliphatic)$, NO_2, CN, CO_2H, $CO_2(C_{1-4}aliphatic)$, $C(O)NH_2$, $C(O)NH(C_{1-4}aliphatic)$, $C(O)N(C_{1-4}aliphatic)_2$, $SO(C_{1-4}aliphatic)$, $SO_2(C_{1-4}aliphatic)$, $SO_2NH(C_{1-4}aliphatic)$, $SO_2NH(C_{1-4}aliphatic)$, $NHC(O)(C_{1-4}aliphatic)$, $N(C_{1-4}aliphatic)C(O)(C_{1-4}aliphatic)$, wherein said C_{1-4}aliphatic is optionally substituted with 1-3 occurrences of halo;

Q^4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 8-10 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each Q^4 is optionally substituted with 1-5 J^{Q4};

J^{Q4} is halo, CN, or C_{1-4}alkyl wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or $S(O)_2$;

R is H or C_{1-4}alkyl wherein said C_{1-4}alkyl is optionally substituted with 1-4 halo;

J^2 is halo; CN; a 5-6 membered aromatic or nonaromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur; or a C_{1-10}aliphatic group wherein up to 2 methylene units are optionally replaced with O, NR", C(O), S, S(O), or $S(O)_2$; wherein said C_{1-10}aliphatic group is optionally substituted with 1-3 halo or CN; and said monocyclic ring is optionally substituted with 1-3 occurences of halo; CN; a C_{3-6}cycloalkyl; a 3-7 membered heterocyclyl containing 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or a C_{1-4}alkyl wherein up to one methylene unit of the alkyl chain is optionally replaced with O, NR", or S; and wherein said C_{1-4}alkyl is optionally substituted with 1-3 halo;

q is 0, 1, or 2;

p is 0 or 1;

R', R", and R* are each independently H, C_{1-4}alkyl, or is absent; wherein said C_{1-4}alkyl is optionally substituted with 1-4 halo.

2. The compound of claim 1, wherein J^P is H.

3. The compound of claim 2, wherein

Y is NH;

R^5 is 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, R^5 is optionally fused to a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from N, O, or S; each R^5 is optionally substituted with 1-5 J^5 groups;

L is –C(O)– or $–SO_2–$;

R^1 is H, or C_1-C_6alkyl;

R^2 is –(C_2-C_6alkyl)–Z or a 4-8 membered cyclic ring containing 0-2 nitrogen atoms; wherein said ring is bonded via a carbon atom and is optionally substituted with one occurrence of J^Z;

or R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 nitrogen atoms; wherein said heterocyclic ring is optionally substituted with one occurrence of J^{Z1};

J^{Z1} is $-(X)_t–CN$, C_1-C_6alkyl or $-(X)_t–Z$;

R^3 is H or C_1-C_2alkyl;

R^4 is H or C_1-C_6alkyl;

or R^3 and R^4, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein said ring is optionally substituted with one occurrence of J^z;

J^5 is halogen, NO_2, CN, O(haloC_{1-4}aliphatic), haloC_{1-4}aliphatic, or a C_{1-6}aliphatic group wherein up to 2 methylene units are optionally replaced with C(O), O, or NR'; and

J^2 is halo, C_1-C_2alkyl optionally substituted with 1-3 fluoro, or CN.


4. The compound of claim 2, wherein L is –C(O)–, m is 0, and R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 nitrogen atoms.

5. The compound of claim 4, wherein said heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, or 1,4-diazepanyl.

6. The compound of any one of claims 1-5, wherein m is 0, q is 0, and $-L-NR^1R^2$ is C(O)pyrrolidinyl, C(O)piperidinyl, C(O)piperazinyl, C(O)azepanyl, C(O) 1,4-diazepanyl, C(O)NH-piperidinyl, C(O)NHCH$_2$CH$_2$-pyrrolidinyl, C(O)NHCH$_2$CH$_2$-piperidinyl, CON(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, wherein said pyrrolidinyl, piperidinyl, piperazinyl, azepanyl or 1,4-diazepanyl is optionally substituted with C_{1-4}alkyl or N(C_{1-4}alkyl)$_2$.


7. The compound of any one of claims 1-6, wherein J^2 is halo, CN, phenyl, oxazolyl, or a C_{1-6}aliphatic group wherein up to 2 methylene units are optionally replaced with O, NR", C(O), S, S(O), or S(O)$_2$; said C_{1-6}aliphatic group is optionally substituted with 1-3 fluoro or CN.

8. The compound of claim 2 having Formula IIA:



IIA

wherein

Ring A is ;

Y is a C_1-C_4alkyl chain wherein one methylene unit of the alkyl chain is optionally replaced with $-NR^0-$;

Q is phenyl or pyridyl substituted in the ortho position, the para position, or in both the ortho and the para position;

R^5 is 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, R^5 is optionally fused to a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from N, O, or S; each R^5 is optionally substituted with 1-5 J^5 groups;

L is $-C(O)-$ or $-SO_2-$;

R^1 is H, or C_1-C_6alkyl;

R^0 is H or C_1-C_6alkyl;

R^2 is C_1-C_6alkyl, $-(C_2$-C_6alkyl$)-Z$ or a 4-8 membered cyclic ring containing 0-2 nitrogen atoms; wherein said ring is bonded via a carbon atom and is optionally substituted with one occurrence of J^Z;

or R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 heteroatoms selected from nitrogen, sulfur, or oxygen; wherein said heterocyclic ring is optionally substituted with one occurrence of J^{Z1};

J^{Z1} is $(X)_t-CN$, C_1-C_6alkyl or $-(X)_r-Z$;

X is C_1-C_4alkyl;

each t, r and m is independently 0 or 1;

Z is $-NR^3R^4$;

R^3 is H or C_1-C_2alkyl;

R^4 is H or C_1-C_6alkyl;

or R^3 and R^4, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein said ring is optionally substituted with one occurrence of J^Z;

J^Z is NH_2, $NH(C_{1-4}aliphatic)$, $N(C_{1-4}aliphatic)_2$, halogen, C_{1-4}aliphatic, OH, $O(C_{1-4}aliphatic)$, NO_2, CN, CO_2H, $CO(C_{1-4}aliphatic)$, $CO_2(C_{1-4}aliphatic)$, $O(haloC_{1-4}aliphatic)$, or $haloC_{1-4}aliphatic$;

J^5 is halogen, NO_2, CN, $O(haloC_{1-4}aliphatic)$, $haloC_{1-4}aliphatic$, or a C_{1-6}aliphatic group wherein up to 2 methylene units are optionally replaced with C(O), O, or NR';


J^2 is halo; CN; phenyl; oxazolyl; or a C_{1-6}aliphatic group wherein up to 2 methylene units are optionally replaced with O, NR", C(O), S, S(O), or $S(O)_2$; said C_{1-6}aliphatic group is optionally substituted with 1-3 fluoro or CN;

R' and R" are each independently H or C_1-C_4 alkyl;

q is 0, 1, or 2; and

p is 0 or 1.

9. The compound of claim 1 or claim 2 having the Formula IA-ii:




IA-ii

or a pharmaceutically acceptable salt thereof; wherein

Y is NH;

Ring A is



;

R^5 is 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, R^5 is optionally fused to a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from N, O, or S; each R^5 is optionally substituted with 1-5 J^5 groups;

L is $-C(O)-$ or $-SO_2-$;

R^1 is H, or C_1-C_6alkyl;

R^2 is $-(C_2$-C_6alkyl$)-Z$ or a 4-8 membered cyclic ring containing 0-2 nitrogen atoms; wherein said ring is bonded via a carbon atom and is optionally substituted with one occurrence of J^Z;

or R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 nitrogen atoms, wherein said heterocyclic ring is optionally substituted with one occurrence of J^{Z1};

J^{Z1} is $-(X)_t-CN$, C_1-C_6alkyl or $-(X)_r-Z$;

X is C_1-C_4alkyl;

each t, r and m is independently 0 or 1;

Z is $-NR^3R^4$;

R^3 is H or C_1-C_2alkyl;


R^4 is H or C_1-C_6alkyl;

or R^3 and R^4, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 nitrogen atoms; wherein said ring is optionally substituted with one occurrence of J^Z;

each J^Z and J^5 is independently NH_2, $NH(C_{1-4}$aliphatic$)$, $N(C_{1-4}$aliphatic$)_2$, halogen, C_{1-4}aliphatic, OH, $O(C_{1-4}$aliphatic$)$, NO_2, CN, CO_2H, $CO(C_{1-4}$aliphatic$)$, $CO_2(C_{1-4}$aliphatic$)$, $O($haloC_{1-4}aliphatic$)$, or haloC_{1-4}aliphatic;

J^2 is halo, C_1-C_2alkyl optionally substituted with 1-3 fluoro or CN;

q is 0, 1, or 2.

10. The compound of claim 9 wherein Ring A is ;

m is 0;

q is 0;

L is $-C(O)-$;

R^1 and R^2, taken together with the atom to which they are bound, form a 4-8 membered heterocyclic ring containing 1-2 nitrogen atoms;


J^{Z1} is $(X)_r$-Z, C_{1-4}alkyl or $N(C_{1-4}$alkyl$)_2$;

R^3 and R^4, taken together with the atom to which they are bound, form a ring selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, or 1,4-diazepanyl.

11. The compound of claim 9, wherein R^1 is H or C_1-C_6alkyl; R^2 is –(C_2-C_6alkyl)–Z, and R^3 and R^4 are both C_1-C_2alkyl.


12. The compound of claim 9, wherein m is 0, q is 0, and –L–NR^1R^2 is C(O)pyrrolidinyl, C(O)piperidinyl, C(O)piperazinyl, C(O)azepanyl, C(O)1,4-diazepanyl, C(O)NH-piperidinyl, C(O)$NHCH_2CH_2$-pyrrolidinyl, C(O)$NHCH_2CH_2$-piperidinyl, $CON(CH_3)CH_2CH_2N(CH_3)_2$, wherein said pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, or 1,4-diazepanyl is optionally substituted with C_{1-4}alkyl or $N(C_{1-4}alkyl)_2$.

13. The compound of claim 1 or claim 2, having Formula IA-iii:




IA-iii:

wherein

Ring A is ,

J^5o is H, F, Cl, C_{1-4}aliphatic, O(C_{1-3}aliphatic), or OH;

J^5p is ;

J^5p1 is H, C_{1-4}aliphatic, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl; wherein J^5p1 is optionally substituted with 1-2 occurrences of OH or halo;


J^5p2 is H, methyl, ethyl, CH_2F, CF_3, or CH_2OH;

J^2o is H, CN, or SO_2CH_3;

J^2m is H, F, Cl, or methyl;


J^2p is $-SO_2(C_{1-6}alkyl)$, $-SO_2(C_{3-6}cycloalkyl)$, $-SO_2$(4-6 membered heterocyclyl), $-SO_2(C_{1-4}alkyl)N(C_{1-4}alkyl)_2$, or $-SO_2(C_{1-4}alkyl)$-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from oxygen, nitrogen, or sulfur; and wherein said J^2p is optionally substituted with 1-3 occurences halo, OH, or $O(C_{1-4}alkyl)$.

14. The compound of claim 13, wherein J^2m is H.
15. The compound of claim 13, wherein J^5o is H.
16. The compound of claim 13, wherein J^2p is $-SO_2(C_{1-6}alkyl)$.
17. The compound of claim 13, wherein




J^5p is ; J^5p1 is CH_3; J^5p2 is H.


18. A compound selected from the following:




IIA-3




IIA-4




IIA-5




IIA-6




IIA-8




IIA-9




IIA-10




IIA-11




IIA-12




IIA-13



IIA-14




IIA-15



IIA-16

19. A compound of formula IIA-7:



IIA-7.

20. A pharmaceutical composition comprising a compound of any one of claims 1-19 and a pharmaceutically acceptable carrier.

21. A compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, according to claim 20, for use in treating cancer in a patient.

22. The compound according to any one of claims 1-19, for use according to claim 21, comprising an additional therapeutic agent selected from cisplatin; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.

23. The compound or composition for use according to any one of claim 21 or claim 22, wherein said cancer is a solid tumor selected from the following cancers: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant


cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.

24. The compound or composition for use according to claim 21, wherein said cancer is selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer and brain cancer.

25. An *ex vivo* method of inhibiting ATR in a biological sample comprising the step of contacting a compound of any one of claims 1-19, with said biological sample.

Claims


1. A compound of **IIA-7**:




IIA-7

or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein the compound is:



3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of




4. A pharmaceutical composition comprising a compound of **IIA-7**:



IIA-7


or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 comprising a compound represented by the following formula:



; and a pharmaceutically acceptable carrier.


6. The pharmaceutical composition of claim 4 comprising a pharmaceutically acceptable



salt of ;

and a pharmaceutically acceptable carrier.


7. A compound of **IIA-7**:



IIA-7

or a pharmaceutically acceptable salt thereof for use in promoting cell death in cancer cells.


8. A compound of **IIA-7**:



IIA-7

or a pharmaceutically acceptable salt thereof for use in preventing cell repair from DNA damage.


9. A compound of **IIA-7**:



IIA-7

or a pharmaceutically acceptable salt thereof for use in inhibiting ATR in a biological sample.


10. A compound of **IIA-7**:




IIA-7

or a pharmaceutically acceptable salt thereof for use in sensitizing cells to DNA damaging agents.

11. The use of any one of claims 7-10, wherein the compound is:



12. The use of any one of claims 7-10, wherein the compound is a pharmaceutically acceptable salt of:



13. The use of any one of claims 9 and 11-12, wherein said biological sample is a cell.

14. The use of any one of claims 10-12, wherein said cell is a cancer cell having a defect in the ATM signaling cascade.

15. The use of claim 14, wherein said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, and H2AX.

16. The use of any one of claims 10-12, wherein said cell is a cancer cell expressing DNA damaging oncogenes.

17. The use of claim 16, wherein said cancer cell has altered expression or activity of one or more of the following: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A, and Rb.